Patient description: The patient is a 34-year-old obese woman who comes to the clinic with weight concerns. She is 165 cm tall, and her weight is 113 kg (BMI: 41.5). In the past, she unsuccessfully used antiobesity agents and appetite suppressants. She is complaining of sleep apnea, PCO and dissatisfaction with her body shape. She is a high-school teacher. She is married for 5 years. She doesn't use any contraceptive methods for the past 4 months and she had no prior pregnancies. She rarely exercises and movement seems to be hard for her. She is not able to complete the four-square step test in less than 15 seconds. She does not smoke or use any drugs. Her BP: 130/80, HR: 195/min and her BMI is: 41.54. Her lab results: FBS: 98 mg/dl TG: 150 mg/dl Cholesterol: 180 mg/dl LDL: 90 mg/dl HDL: 35 mg/dl She is considering a laparoscopic gastric bypass.

Clinical trial eligibility criteria: eligible ages (years): 0.115-999.0,  Apnea Apnea Neonatal Prematurity ≤32 weeks gestational age at birth 2. ≥6 weeks postnatal age at randomization 3. Remains hospitalized after birth (has never been discharged home) 4. Treating clinician deems infant eligible to receive 2-month vaccines 5. English or Spanish-speaking parent(s)/legally authorized representative(s) (LAR(s)) 6. Not planned for discharge within 60 hours of study entry 7. The parent/guardian must be willing and capable of providing permission for their child to participate through the written informed consent process  Receipt of DTaP, IPV, PCV13, or Hib prior to enrollment. Previous administration of the first dose of HBV is permitted 2. Anticipated receipt of any vaccine other than DTaP, IPV, HBV, PCV13, or Hib during the first 60 hours after randomization 3. History of a severe allergic reaction (e.g. anaphylaxis) to a previous dose of any hepatitis B vaccine 4. History of a severe allergic reaction (e.g. anaphylaxis) to any component of the vaccines used in the study including neomycin, yeast and polymyxin B 5. History of latex allergy 6. Fever ≥38°C within 48 hours prior to randomization* *This may result in a temporary delay of randomization 7. Active known respiratory infection within 48 hours prior to randomization* *This may result in a temporary delay of randomization 8. Active infection being treated with systemic antimicrobials* *This may result in a temporary delay of randomization 9. Requiring mechanical ventilation or support with nasal intermittent positive pressure ventilation (NIPPV)* *This may result in a temporary delay of randomization 10. History of unstable progressive neurologic disorder of unknown cause 11. Known cause of apnea other than apnea of prematurity 12. Cyanotic heart disease (congenital or acquired) 13. Major invasive medical or surgical procedure (including circumcision) within 48 hours prior to randomization or anticipated to have major invasive medical or surgical procedure during the first 60 hours after randomization* *This may result in a temporary delay of randomization 14. Child or parent/LAR is an immediate relative of study staff or an employee who is supervised by study staff. 15. Any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol